Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574753 · ClinicalTrials.gov registry record · Phase 2
Lung-MAP S1400K: c-MET Positive
A Phase 2 study of Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03574753 is a Phase 2 study of Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7 that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 28 participants, below the 153-participant average among 3 other Recurrent Squamous Cell Lung Carcinoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03574753, a Phase 2 study of Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.
Conditions Studied
Interventions
- DRUG ABBV-399
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-03-16 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03574753
The ClinicalTrials.gov registry entry for NCT03574753 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 3 other Recurrent Squamous Cell Lung Carcinoma trials with a reported enrollment target (82% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Squamous Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ABBV-399 is the first listed.
NCT03574753 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03574753 about?
NCT03574753 is a clinical study titled "Lung-MAP S1400K: c-MET Positive". S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.
What is the current status of trial NCT03574753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2018-03-16. Estimated completion is 2021-07-30.
What conditions does trial NCT03574753 study?
This clinical trial studies the following conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7.
What interventions are being tested in trial NCT03574753?
The interventions under investigation include: ABBV-399 (DRUG).
Who is sponsoring clinical trial NCT03574753?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03574753 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Squamous Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
COMPLETED · Phase 2
-
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
COMPLETED · Phase 2
-
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Recurrent Squamous Cell Lung Carcinoma
All registered trials for this condition
Stage IV Squamous Cell Lung Carcinoma AJCC v7
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.